REFERENCES

1. Kok K, Zwiers KC, Boot RG, Overkleeft HS, Aerts JMFG, Artola M. Fabry disease: molecular basis, pathophysiology, diagnostics and potential therapeutic directions. Biomolecules 2021;11:271.

2. Ryckman AE, Brockhausen I, Walia JS. Metabolism of glycosphingolipids and their role in the pathophysiology of lysosomal storage disorders. Int J Mol Sci 2020;21:6881.

3. Perretta F, Antongiovanni N, Jaurretche S. Major organic involvement in women with fabry disease in argentina. Sci World J 2018;2018:6515613.

4. Ramaswami U, Whybra C, Parini R, et al. Clinical manifestations of Fabry disease in children: data from the Fabry outcome survey. Acta Paediatr 2006;95:86-92.

5. Caputo F, Lungaro L, Galdi A, et al. Gastrointestinal involvement in anderson-Fabry disease: a narrative review. Int J Environ Res Public Health 2021;18:3320.

6. Pieroni M, Moon JC, Arbustini E, et al. Cardiac involvement in Fabry disease: JACC review topic of the week. J Am Coll Cardiol 2021;77:922-36.

7. Silva CAB, Moura-Neto JA, Dos Reis MA, Vieira Neto OM, Barreto FC. Renal manifestations of Fabry disease: a narrative review. Can J Kidney Health Dis 2021;8:2054358120985627.

8. Mishra V, Banerjee A, Gandhi AB, et al. Stroke and Fabry disease: a review of literature. Cureus 2020;12:e12083.

9. Germain DP. Fabry disease. Orphanet J Rare Dis 2010;5:30.

10. Kant S, Atta MG. Therapeutic advances in Fabry disease: the future awaits. Biomed Pharmacother 2020;131:110779.

11. Lenders M, Brand E. Fabry disease: the current treatment landscape. Drugs 2021;81:635-45.

12. EMA. Elfabrio. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/elfabrio [Last accessed on 21 Jun 2024].

13. FDA. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761161s000lbl.pdf [Last accessed on 21 Jun 2024].

14. McCafferty EH, Scott LJ. Migalastat: a review in Fabry disease. Drugs 2019;79:543-54.

15. Felis A, Whitlow M, Kraus A, Warnock DG, Wallace E. Current and investigational therapeutics for Fabry disease. Kidney Int Rep 2020;5:407-13.

16. Khan A, Barber DL, Huang J, et al. Lentivirus-mediated gene therapy for Fabry disease. Nat Commun 2021;12:1178.

17. Simonetta I, Tuttolomondo A, Daidone M, Pinto A. Biomarkers in anderson-Fabry disease. Int J Mol Sci 2020;21:8080.

18. Carnicer-Cáceres C, Arranz-Amo JA, Cea-Arestin C, et al. Biomarkers in Fabry disease. Implications for clinical diagnosis and follow-up. J Clin Med 2021;10:1664.

19. Bengtsson BA, Johansson JO, Hollak C, Linthorst G, FeldtRasmussen U. Enzyme replacement in anderson-Fabry disease. Lancet 2003;361:352.

20. Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-9.

21. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry’s disease. N Engl J Med 2001;345:9-16.

22. Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 2008;105:2812-7.

23. Dupont FO, Gagnon R, Boutin M, Auray-Blais C. A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease biomarkers. Curr Med Chem 2013;20:280-8.

24. Auray-Blais C, Boutin M, Gagnon R, Dupont FO, Lavoie P, Clarke JT. Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics. Anal Chem 2012;84:2745-53.

25. Manwaring V, Boutin M, Auray-Blais C. A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients. Anal Chem 2013;85:9039-48.

26. Auray-Blais C, Boutin M. Novel Gb3 isoforms detected in urine of Fabry disease patients: a metabolomic study. Curr Med Chem 2012;19:3241-52.

27. Auray-Blais C, Lavoie P, Boutin M, et al. Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation. Clin Chim Acta 2017;466:185-93.

28. Auray-Blais C, Blais CM, Ramaswami U, et al. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry. Clin Chim Acta 2015;438:195-204.

29. Lavoie P, Boutin M, Auray-Blais C. Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry. Anal Chem 2013;85:1743-52.

30. Finkelstein JD. Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine. Clin Chem Lab Med 2007;45:1694-9.

31. Lohse B, Kristensen JL, Kristensen LH, et al. Inhibitors of histone demethylases. Bioorg Med Chem 2011;19:3625-36.

32. Bai HW, Shim JY, Yu J, Zhu BT. Biochemical and molecular modeling studies of the O-methylation of various endogenous and exogenous catechol substrates catalyzed by recombinant human soluble and membrane-bound catechol-O-methyltransferases. Chem Res Toxicol 2007;20:1409-25.

33. Patti GJ, Yanes O, Shriver LP, et al. Metabolomics implicates altered sphingolipids in chronic pain of neuropathic origin. Nat Chem Biol 2012;8:232-4.

34. Abaoui M, Boutin M, Lavoie P, Auray-Blais C. High-risk screening of Fabry disease: analysis of fifteen urinary methylated and non-methylated Gb₃ isoforms using tandem mass spectrometry. Curr Protoc Hum Genet 2016;91:17.24.1-11.

35. Abaoui M, Boutin M, Lavoie P, Auray-Blais C. Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb₃ isoforms in Fabry disease patients. Clin Chim Acta 2016;452:191-8.

36. Lavoie P, Boutin M, Abaoui M, Auray-Blais C. Fabry disease biomarkers: analysis of urinary lyso-Gb3 and seven related analogs using tandem mass spectrometry. Curr Protoc Hum Genet 2016;90:17.22.1-12.

37. Boutin M, Lavoie P, Abaoui M, Auray-Blais C. Tandem mass spectrometry quantitation of lyso-Gb3 and six related analogs in plasma for Fabry disease patients. Curr Protoc Hum Genet 2016;90:17.23.1-9.

38. Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, Krivit W. Fabry’s disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med 1973;81:157-71.

39. Thurberg BL, Rennke H, Colvin RB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002;62:1933-46.

40. Chatterjee S, Gupta P, Pyeritz RE, Kwiterovich PO Jr. Immunohistochemical localization of glycosphingolipid in urinary renal tubular cells in Fabry’s disease. Am J Clin Pathol 1984;82:24-8.

41. Schiffmann R, Waldek S, Benigni A, Auray-Blais C. Biomarkers of Fabry disease nephropathy. Clin J Am Soc Nephrol 2010;5:360-4.

42. Fall B, Scott CR, Mauer M, et al. Urinary podocyte loss is increased in patients with Fabry disease and correlates with clinical severity of Fabry nephropathy. PLoS One 2016;11:e0168346.

43. Najafian B, Tøndel C, Svarstad E, Gubler MC, Oliveira JP, Mauer M. Accumulation of Globotriaosylceramide in podocytes in Fabry nephropathy is associated with progressive podocyte loss. J Am Soc Nephrol 2020;31:865-75.

44. Shiga T, Tsukimura T, Namai Y, Togawa T, Sakuraba H. Comparative urinary globotriaosylceramide analysis by thin-layer chromatography-immunostaining and liquid chromatography-tandem mass spectrometry in patients with Fabry disease. Mol Genet Metab Rep 2021;29:100804.

45. Moura AP, Hammerschmidt T, Deon M, Giugliani R, Vargas CR. Investigation of correlation of urinary globotriaosylceramide (Gb₃) levels with markers of renal function in patients with Fabry disease. Clin Chim Acta 2018;478:62-7.

46. Vedder AC, Linthorst GE, van Breemen MJ, et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 2007;30:68-78.

47. Nowak A, Mechtler TP, Hornemann T, et al. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease. Mol Genet Metab 2018;123:148-53.

48. Nowak A, Beuschlein F, Sivasubramaniam V, Kasper D, Warnock DG. Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease. J Med Genet 2022;59:287-93.

49. Niemann M, Rolfs A, Störk S, et al. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet 2014;7:8-16.

50. Nikolaenko V, Warnock DG, Mills K, Heywood WE. Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry disease. Hum Mol Genet 2023;32:2464-72.

51. Hwang AR, Park S, Woo CH. Lyso-globotriaosylsphingosine induces endothelial dysfunction via autophagy-dependent regulation of necroptosis. Korean J Physiol Pharmacol 2023;27:231-40.

52. Sanchez-Niño MD, Sanz AB, Carrasco S, et al. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant 2011;26:1797-802.

53. Choi L, Vernon J, Kopach O, et al. The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain. Neurosci Lett 2015;594:163-8.

54. van der Veen SJ, Sayed ME, Hollak CEM, et al. Early risk stratification for natural disease course in Fabry patients using plasma globotriaosylsphingosine levels. Clin J Am Soc Nephrol 2023;18:1272-82.

55. Ouyang Y, Zhang W, Zhao Z, et al. Globotriaosylsphingosine improves risk stratification of kidney progression in Fabry disease patients. Clin Chim Acta 2024;556:117851.

56. Duro G, Zizzo C, Cammarata G, et al. Mutations in the GLA gene and LysoGb3: is it really anderson-Fabry disease? Int J Mol Sci 2018;19:3726.

57. Ferreira S, Auray-Blais C, Boutin M, et al. Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma. Clin Chim Acta 2015;447:96-104.

58. Germain DP, Altarescu G, Barriales-Villa R, et al. An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease. Mol Genet Metab 2022;137:49-61.